Compare Etsy Inc (ETSY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Mesoblast Limited — how do they compare? Etsy Inc trades at $84.51 (market cap $8.14B), while Mesoblast Limited trades at $18.66 (market cap $2.31B). The key difference: Etsy Inc is far larger — about 3.5× Mesoblast Limited's market cap, and Etsy Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ETSY | MESO | |
|---|---|---|
Market Cap | $8.14B | $2.31B |
Sector | Consumer Cyclical | Technology |
52-Week High | $85.74 | $20.96 |
52-Week Low | $44.05 | $11.35 |
Enterprise Value | $9.79B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $84.30, up 1.49% today, with a bullish technical signal from moving averages. The stock shows strong earnings beats in recent quarters but faces declining revenue and net income margins year-over-year. Positive sentiment is driven by AI-powered seller tools and app engagement growth, though active buyer declines remain a concern. Cash flow improved significantly in 2025 to $593 million.
Outlook is mixed: analyst consensus is cautious with a $72.38 price target below current levels, but technical momentum and AI initiatives offer upside potential. Key risks include high debt, competitive pressure, and inconsistent profitability. Institutional sentiment leans bullish with 49% buy ratings.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
